ORPH

Orphazyme A/S

Price

return (12m)

p/e

0.00

p/bv

0.00

DIVIDEND YIELD

0.00%

ORPH price

Orphazyme

If you had invested

exposure

years ago

ago, you would now have *

ago, you would now have:

*This calculation reflects price variation only.

Return on Investment ORPH

1 month

3 months

1 year

2 years

5 years

10 years

return

1 month

0.00%

3 months

0.00%

1 year

0.00%

2 years

0.00%

5 years

0.00%

10 years

0.00%

Asset Comparator

If you had invested

years ago

ago, you would now have *

ago, you would now have:

*This calculation reflects price variation only.

Fundamentals ORPH

Valuation

P/E

0.00

Sector -4.23

Industry -4.23

P/BV

0.00

Sector 2.11

Industry 2.11

P/Revenue (PSR)

Sector 2.05

Industry 2.05

EV/EBITDA

Sector -546.75

Industry -546.75

EV/EBIT

Sector -37.85

Industry -37.85

P/EBITDA

Sector -51.33

Industry -51.33

P/EBIT

Sector -39.56

Industry -39.56

P/Total Assets

Sector 1.25

Industry 1.25

P/Net Current Assets

Sector -5.36

Industry -5.36

P/Working Capital

Sector -1.24

Industry -1.24

EPS

Sector -1.92

Industry -1.92

BVPS

Sector 1.93

Industry 1.93

Efficiency

Gross Margin

0.00%

Sector 39.10%

Industry 39.10%

EBITDA Margin

Sector -13,872.36%

Industry -13,872.36%

EBIT Margin

Sector -4,235,733.26%

Industry -4,235,733.26%

Operating Margin

0.00%

Sector -36.62%

Industry -36.62%

Net Profit Margins

0.00%

Sector -37.41%

Industry -37.41%

Asset Turnover

Sector 0.03

Industry 0.03

Profitability

ROE

0.00%

Sector -60.49%

Industry -60.49%

ROA

0.00%

Sector -63.06%

Industry -63.06%

ROIC

Sector -498.28%

Industry -498.28%

Dividends

Dividend yield

0.00%

Sector -

Industry -

Payout

Sector -

Industry -

Debt

Current Ratio

Sector 2.90

Industry 2.90

Net Debt / EBITDA

Sector -39,048,222.71

Industry -39,048,222.71

Net Debt / EBIT

Sector -10.24

Industry -10.24

Net Debt / Equity

Sector -38,821.65

Industry -38,821.65

Gross Debt / Equity

Sector -0.83

Industry -0.83

Equity/Assets

Sector 0.43

Industry 0.43

Liabilities/Assets

Sector 0.39

Industry 0.39

Growth

5Y Revenue CAGR

0.00%

Sector -

Industry -

5Y Earnings CAGR

0.00%

Sector -

Industry -

Fundamentals ORPH

DRAG THE FRAME TO SEE MORE DATA

Assets	Price (US$)	Return 12m	DY	P/E	P/BV	ROE	Net Profit Margins
ORPH Orphazyme A/S	$0.00	-	0.00%	0.00	0.00	0.00%	0.00%
JNJ Johnson & Johnson	$276.47	60.00%	1.98%	30.34	7.51	24.76%	21.48%
PFE Pfizer Inc.	$28.64	23.67%	6.28%	35.72	1.83	5.11%	6.86%
ABBV AbbVie Inc.	$257.20	25.27%	2.66%	72.02	-76.66	-106.44%	9.81%
NVO Novo Nordisk A/S	$46.74	-12.60%	4.06%	11.16	5.92	53.11%	35.32%
MRK Merck & Co. Inc.	$150.67	85.97%	2.29%	114.53	8.64	7.55%	4.76%
AZN AstraZeneca PLC	$162.57	1.81%	1.99%	23.89	4.95	20.74%	17.02%
BMY Bristol-Myers Squibb Company	$66.95	47.63%	3.79%	14.60	6.06	41.55%	18.85%
ZTS Zoetis Inc.	$75.67	-49.40%	2.68%	12.14	10.20	84.02%	27.77%
AMGN Amgen Inc.	$438.54	60.04%	2.28%	26.55	19.86	74.80%	22.95%
REGN Regeneron Pharmaceuticals Inc.	$834.48	47.70%	0.58%	18.86	2.57	13.65%	27.86%
HALO Halozyme Therapeutics Inc.	$110.01	47.03%	0.00%	29.70	85.59	288.14%	24.86%
MCK McKesson Corporation	$917.36	33.47%	0.37%	20.12	-27.60	-137.16%	1.29%
VRTX Vertex Pharmaceuticals Incorporated	$551.38	39.02%	0.00%	31.27	6.80	21.76%	35.00%
CAH Cardinal Health Inc.	$247.79	66.68%	0.87%	35.62	-20.64	-57.93%	0.62%
HRMY Harmony Biosciences Holdings Inc.	$42.15	12.31%	0.00%	12.57	2.28	18.14%	18.89%
ARGX argenx SE	$1,038.19	43.79%	0.00%	3.11	3.48	112.18%	44.41%

Stock vs Indice Comparison Tool

If you had invested

years ago

ago, you would now have *

ago, you would now have:

*This calculation reflects price variation only.

ORPH Historical Dividends

current DY: 0.00%

5-year average DY: 0.00%

no dividend paid in the period.

ABOUT Orphazyme

Orphazyme A/S

Average Investor10 user rating

4.0 (0 people)

United States

17 years

Founded: 2009

2020

Time since IPO - 6 years

141

Employees

Orphazyme A/S (United States) is listed on the Nasdaq and has a market capitalization of $11.81 million, with shareholders equity totaling $-.

The company employs approximately 141 people and operates in the Health Care sector, within the Biotechnology industry.

Over the past 12 months, Orphazyme A/S reported $- in revenue, generating net income of $-.

Key financial metrics include a P/E ratio of 0.00, a price-to-book (P/B) ratio of 0.00, and a trailing twelve-month dividend yield of 0.00%.

The company trades under the ticker ORPH.

Market cap

$11.81 million

Net worth

Assets

Total Shares Outstanding

34.95 million

34,952,000

Average Daily Trading Volume

$1.07 million

$1,070,941.56

Sector

Health Care

Industry

Biotechnology

ORPH

ORPH revenue and profits

Financial Results ORPH

DRAG THE FRAME TO SEE MORE DATA

ORPH cash flow

DRAG THE FRAME TO SEE MORE DATA

Discover more assets

BFRA - Biofrontera

$- -0,00% (12M)

P/E

0.00

0.00%

ROE

-893.55%

P/BV

0.00

MCK - McKesson

$917.36 34,14% (12M)

P/E

20.12

0.37%

ROE

-137.16%

P/BV

-27.60

CAH - Cardinal Health

$247.79 67,79% (12M)

P/E

35.62

0.87%

ROE

-57.93%

P/BV

-20.64

JNJ - Johnson & Johnson

$276.47 59,62% (12M)

P/E

30.34

1.98%

ROE

24.76%

P/BV

7.51

ABBV - AbbVie

$257.20 24,86% (12M)

P/E

72.02

2.66%

ROE

-106.44%

P/BV

-76.66

MRK - Merck & Co.

$150.67 84,80% (12M)

P/E

114.53

2.29%

ROE

7.55%

P/BV

8.64

AZN - AstraZeneca

$162.57 1,38% (12M)

P/E

23.89

1.99%

ROE

20.74%

P/BV

4.95

PFE - Pfizer

$28.64 23,22% (12M)

P/E

35.72

6.28%

ROE

5.11%

P/BV

1.83

BFRA - Biofrontera

$- -0,00% (12 M)

P/L

0.00

0.00%

ROE

-893.55%

P/VP

0.00

MCK - McKesson

$917.36 34,14% (12 M)

P/L

20.12

0.37%

ROE

-137.16%

P/VP

-27.60

CAH - Cardinal Health

$247.79 67,79% (12 M)

P/L

35.62

0.87%

ROE

-57.93%

P/VP

-20.64

JNJ - Johnson & Johnson

$276.47 59,62% (12 M)

P/L

30.34

1.98%

ROE

24.76%

P/VP

7.51

ABBV - AbbVie

$257.20 24,86% (12 M)

P/L

72.02

2.66%

ROE

-106.44%

P/VP

-76.66

MRK - Merck & Co.

$150.67 84,80% (12 M)

P/L

114.53

2.29%

ROE

7.55%

P/VP

8.64

AZN - AstraZeneca

$162.57 1,38% (12 M)

P/L

23.89

1.99%

ROE

20.74%

P/VP

4.95

PFE - Pfizer

$28.64 23,22% (12 M)

P/L

35.72

6.28%

ROE

5.11%

P/VP

1.83

Frequently Asked Questions

What is the price of Orphazyme (ORPH) today?

A cotação de Orphazyme (ORPH) hoje está em US$ 0.00, com uma variação de 0% em relação ao último ano. A cotação de Orphazyme (ORPH) iniciou o ano negociando na casa dos US$ 0.00 e hoje está em US$ 0.00. Acompanhe o gráfico de cotação em tempo real, a cotação histórica de Orphazyme (ORPH) e dados de ações do Ibovespa e mercados internacionais.

Quando Orphazyme (ORPH) paga dividendos?

Orphazyme (ORPH) não distribuiu dividendos no último ano.

Is Orphazyme (ORPH) a good investment?

Atualmente, Orphazyme (ORPH) está cotada a US$ 0.00, com um P/L de 0.00, representando um desvio de 0% em relação ao seu P/L médio histórico. No último ano, a ação apresentou uma variação de 0 em sua cotação e distribuiu US$ 0.00 em dividendos, resultando em um Dividend Yield de 0.00%. O retorno total do acionista foi de 0.00%.

Investors should keep in mind that past performance does not guarantee future results. This information is provided for educational purposes only and should not be considered investment advice.

How can I buy Orphazyme (ORPH) stock?

Investir em ações de Orphazyme (ORPH) pode ser feito de duas formas: comprando a stock uma empresa estrangeira e é atrelado ao dólar.

How much would 100 shares of Orphazyme (ORPH) yield today?

A rentabilidade de Orphazyme (ORPH) foi de 0.00% no último mês, 0.00% no último ano e 0.00% nos últimos 5 anos (já considerando valorização e dividendos).

Nos últimos 12 meses, a empresa pagou um total de US$ 0.00 em dividendos, um Dividend Yield de 0.00%.

Se você quisesse comprar 100 ações de Orphazyme (ORPH) hoje, o investimento total seria de US$ 0.00, com base na cotação atual de US$ 0.00.

Based on historical performance, the investment would have grown to approximately:

Em 1 ano: US$ 0.00
Em 5 anos: US$ 0.00
Em 10 anos: US$ 0.00

Past performance does not guarantee future results. This content is for informational purposes only and should not be considered investment advice.

ORPH

Orphazyme A/S

Price

return (12m)

p/e

p/bv

DIVIDEND YIELD

Return on Investment ORPH

Valuation

Efficiency

Profitability

Dividends

Debt

Growth

COMPARING ORPH WITH OTHER STOCK

current DY: 0.00%

5-year average DY: 0.00%

ABOUT Orphazyme

Orphazyme A/S

United States

17 years

2020

141

Financial Results ORPH

ORPH cash flow

Asset, Revenue and Profit Growth - ORPH

ORPH balance sheet

BFRA - Biofrontera

MCK - McKesson

CAH - Cardinal Health

JNJ - Johnson & Johnson

ABBV - AbbVie

MRK - Merck & Co.

AZN - AstraZeneca

PFE - Pfizer

BFRA - Biofrontera

MCK - McKesson

CAH - Cardinal Health

JNJ - Johnson & Johnson

ABBV - AbbVie

MRK - Merck & Co.

AZN - AstraZeneca

PFE - Pfizer

Frequently Asked Questions